6- and 7-amino isoquinoline compounds are provided that influence, inhibit or reduce the action of a kinase. Pharmaceutical compositions including therapeutically effective amounts of the 6- and 7-aminoisoquinoline compounds and pharmaceutically acceptable carriers are also provided. Various methods using the compounds and/or compositions to affect disease states or conditions such as cancer, obesity and glaucoma are also provided.

Claims

14 · 2 independent · depth 4

14 granted claims

›1.independentA compound of the formula:+11

›2.↳ 1A compound according to claim 1, wherein the compound is of the formulad2

›3.↳ 1A compound according to claim 1, wherein R1 is 2-thienyl.d2

›4.↳ 1A compound according to claim 1, wherein R1 is 3-thienyl.d2

›5.↳ 1A compound according to claim 1, wherein R2 and R3 are both H.d2

›6.↳ 1A compound according to claim 1, wherein R2 and R3 are both C1-C4 alkyl.d2

›7.↳ 1A compound according to claim 1, wherein R5 is OH.d2

›9.↳ 1A pharmaceutical composition comprising a compound according to claim 1 and a carrier.d2

›11.↳ 1A method for treating a disease in a mammal comprising administering to a mammal a safe and effective amount of a compound according to claim 1, where…d2+3

›8.independentA compound of formula+1

Classifications

5 codes

IPC · International Patent Classification

Section A — Human necessities

A61K31/47

Section C — Chemistry; metallurgy

C07D401/04

USPC · US Patent Classification

514/307546/146546/141

Claim changes

Soon

Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this patent are not paired with the granted ones in what we hold.

File wrapper

Pendency

4.2 y

1,545 days filing → grant

Office actions

after a restriction

Responses

2 RCE

Interviews

examiner interview summaries

Examiner

Zinna Northington Davis

art unit 1625 · TC 1600

Law firm

Law firm · Log in to unlock

Citations: 154 back · 0 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Term & fees

See the term timeline — pendency span, in-force span, the maintenance fees paid and both computed expiry dates.

Priority chain

1 priority documents

›Priority documents — 1

Type	Document	Date
related publication	US 20090186917 A1	23 Jul 2009

Validity challenges

See the validity challenges on record — reexaminations, IPRs and PGRs, with their institution decisions and outcomes.

Citations

See every patent this one cites and every patent that cites it back — publication, assignee, and how each one was found.